Publication:
Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulation

Simple item page
dc.contributor.authorWang, Qiuhan
dc.contributor.authorHao, Fengyun
dc.contributor.authorNing, Liang
dc.contributor.authorSun, Chong
dc.date.accessioned2024-09-09T07:58:40Z
dc.date.available2024-09-09T07:58:40Z
dc.date.issued2024
dc.description.abstractPseudopodium-enriched atypical kinase 1 (PEAK1) has been demonstrated to be upregulated in human malignancies and cells. Enhanced PEAK1 expression facilitates tumor cell survival and chemoresistance. However, the role of PEAK1 inhibition to anaplastic thyroid carcinoma cell (ATC) and vemurafenib resistance is still unknown. Here, we observed that targeting PEAK1 inhibited cell viability and colony formation, but not cell apoptosis in both of the 8505C and Hth74 cells in vitro. Targeting PEAK1 sensitized 8505C and Hth74 cells to Vemurafenib by inducing cell apoptosis, and thereby decreasing cell viability. Mechanistically, Vemurafenib treatment upregulated PEAK1 expression. Combined PEAK1 depletion and Vemurafenib treatment upregulated Bim expression. Targeting PEAK1 sensitized Vemurafenib-induced apoptosis by upregulating Bim. In conclusion, Vemurafenib resistance in ATC cells harboring BRAFV600E is associated with PEAK1 activation, resulting in the inhibition of pro-apoptotic Bim protein. Therefore, targeting PEAK1 may be an effective strategy to sensitize ATC harboring BRAFV600E to Vemurafenib.es
dc.formatapplication/pdfes
dc.format.extent7es
dc.identifier.citationHistology and Histopathology Vol. 39, nº9 (2024)
dc.identifier.doihttps://doi.org/10.14670/HH-18-705
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/143723
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectAnaplastic thyroid carcinomaes
dc.subjectBRAF inhibitorses
dc.subjectVemurafenibes
dc.subjectApoptosises
dc.subjectChemoresistancees
dc.subjectPseudopodium-enriched atypical kinasees
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleTargeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAFV600E to Vemurafenib by Bim upregulationes
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Wang-39-1159-1165-2024.pdf
Size:
742.03 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.26 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.39, nº9 (2024)